The GLP-1 Era: How Weight-Loss Drugs Changed Us
Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024

Search
52 stories for“weight loss”
Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024

Work in EMBO Reports finds obesity leaves a chemical mark on CD4 T cells that outlasts weight loss. The authors suggest the immune system may need years of sustained maintenance to reset, and say plainly that no long term human study confirms it.
Sep 1, 2026

Tirzepatide just earned an approval that has nothing to do with the scale. Here is what SELECT, FLOW and the new sleep apnea data show.
Jan 8, 2025

Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024

Trial data on stopping semaglutide shows most of the lost weight comes back within a year. Here is what the STEP 1 extension found.
May 15, 2024

New body composition data compares lean mass loss on tirzepatide and semaglutide. Here is what is measured, and what remains unclear.
Jun 15, 2026

TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026

Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024

Three randomised trials put time-restricted eating against ordinary calorie control or against nothing. The eating window on its own did little. Combined with eating less, it did what eating less does. What that means for anyone considering it.
Sep 6, 2026

Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026

Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024

Ozempic, Mounjaro and the drug that has not arrived yet are not three versions of the same thing. They hit different receptors, produce different results, and suit different people.
Aug 11, 2026

Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024

DiRECT reported 46 per cent remission at one year and 36 per cent at two. Among those who lost more than ten kilograms, three quarters were in remission. At five years, the picture is more sobering and more useful.
Aug 12, 2026

Ozempic, Wegovy and Mounjaro are all prescribable in the UAE, but shortages and insurance gaps shape who can actually get them.
Mar 10, 2025

GLP-1 receptor agonists did not start as weight loss drugs. Here is the biology behind Ozempic, Mounjaro and the hormone they mimic.
Jan 25, 2024

In 1,900 American adults, waist circumference on its own matched a new multi measurement framework against a proper body fat scan. BMI alone missed a substantial number of people who met the body fat criteria for obesity.
Sep 1, 2026

Trials now show insufficient sleep impairs insulin sensitivity directly, independent of weight gain, reshaping how doctors talk about diabetes risk.
Nov 2, 2024

Doctors and followers spent a year disagreeing about nizam al-tayyibat without ever contradicting each other, because they were not answering the same question.
Jul 24, 2026

Contracting muscle opens a separate doorway for glucose that does not require insulin at all. It explains why a ten minute walk after dinner works, why lifting weights matters more than it is given credit for, and why a hard sprint can send the number up.
Aug 9, 2026

Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026

The label is contested, the thresholds differ between guidelines, and most people who have it never progress. It is also the one point in this whole condition where a trial showed you can change the outcome by more than half.
Jul 10, 2026

One patient cannot bear a bedsheet touching their feet. Another cannot feel a nail through their shoe. Both have diabetic neuropathy, and the second is in more danger than the first.
Jul 28, 2026

A physiologist went looking for the origin of the rule in 2002 and came back empty. What the reference intakes actually say, why food and coffee count, how much the number varies between people, and when in a Gulf summer it genuinely matters.
Sep 6, 2026

Diabetes care is organised around bringing numbers down, which makes it easy to forget that the acute danger points the other way. The ADA defines three levels of hypoglycaemia, and the third one requires another person.
Aug 6, 2026

The test everyone treats as the verdict measures sugar stuck to haemoglobin over the life of a red cell. Anything that changes how long those cells live changes the result, and several of those conditions are common across this region.
Jul 13, 2026

Lilly does not expect to file for approval until the first quarter of 2027. Search the drug's name today and you can have a vial by the weekend. The gap between those two facts is where the harm happens.
Aug 20, 2026

Coeliac blood tests look for antibodies your body only makes while you are eating gluten. Cut it out first and the result can come back clear while the disease carries on.
Jul 16, 2026

Mail-in stool tests promise personalized nutrition insight, but the same sample sent to different labs can come back with conflicting advice.
Oct 3, 2025
